NCT06818812View on ClinicalTrials.gov

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

March 27, 2027

Study Completion Date

March 27, 2027

Conditions
Solid Tumors
Interventions
DRUG

INCB186748

INCB186748 will be administered at protocol defined dose.

DRUG

Cetuximab

Cetuximab will be administered at protocol defined dose.

DRUG

GEMNabP

GEMNabP will be administered at protocol defined dose.

DRUG

mFOLFIRINOX

mFOLFIRINOX will be administered at protocol defined dose.

Trial Locations (9)

19107

Jefferson University Hospitals, Philadelphia

20007

Georgetown University Hospital, Washington D.C.

34232

Florida Cancer Specialists, Sarasota

37203

Scri Oncology Partners, Nashville

77030

Md Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institue At Healthone, Denver

90404

UCLA Healthcare Hematology-Oncology, Santa Monica

21287-7049

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY